Literature DB >> 12820424

Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas.

T Rost1, V Pyritz, I O Rathcke, T Görögh, A A Dünne, J A Werner.   

Abstract

BACKGROUND: Besides other molecular functions, the lysyl oxidase gene (LOX) has been assumed and shown to have a tumor suppressive function in vitro and in vivo. The cancer-related functions of both LOX and LOXL2 have not yet been investigated in squamous cell carcinoma of the head and neck (HNSCC).
MATERIALS AND METHODS: We examined the mRNA levels of LOX and LOXL2 in ten malignantly transformed cell lines and sixteen malignant tissue samples of different graded and staged HNSCC by RT-PCR.
RESULTS: The LOX-mRNA level in both cell lines and tissues of HNSCC was markedly reduced as opposed to benign keratinocyte cell lines and mucosal tissue samples of the upper aerodigestive tract. Similar results were shown for LOXL2-mRNA levels in cell lines, whereas no reduction of LOXL2-mRNA levels was found in the malignantly transformed tissues.
CONCLUSION: These findings support the presumption that LOX is involved in tumor suppressive processes and also of LOXL2 playing a role in malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820424

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.

Authors:  Ping Zhan; Xiao-Kun Shen; Qian Qian; Ji-Ping Zhu; Yu Zhang; Hai-Yan Xie; Chuen-Hua Xu; Ke-Ke Hao; Wei Hu; Ning Xia; Guo-Jun Lu; Li-Ke Yu
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

2.  Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia.

Authors:  Hiroaki Kasashima; Masakazu Yashiro; Haruhito Kinoshita; Tatsunari Fukuoka; Tamami Morisaki; Go Masuda; Katsunobu Sakurai; Naoshi Kubo; Masaichi Ohira; Kosei Hirakawa
Journal:  Gastric Cancer       Date:  2015-06-23       Impact factor: 7.370

3.  Effects of lysyl oxidase genetic variants on the susceptibility to rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

Authors:  Honghua Yu; Tao Li; Xiulan Zou; Ling Yuan; Jie Hu; Zhe Xu; Lianghong Peng; Chu Zhang; Yuping Zou
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

4.  The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.

Authors:  Seiichi Sato; Philip C Trackman; Joni M Mäki; Johanna Myllyharju; Kathrin H Kirsch; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

Review 5.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

6.  Lysyl oxidase, extracellular matrix remodeling and cancer metastasis.

Authors:  Qian Xiao; Gaoxiang Ge
Journal:  Cancer Microenviron       Date:  2012-04-13

7.  Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Newbold; Kefah Mokbel
Journal:  J Carcinog       Date:  2010-11-12

8.  A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Authors:  Chengyin Min; Ziyang Yu; Kathrin H Kirsch; Yingshe Zhao; Siddharth R Vora; Philip C Trackman; Douglas B Spicer; Lynn Rosenberg; Julie R Palmer; Gail E Sonenshein
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  The effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancer.

Authors:  Weiwei Shi; Bo Yang; Xiaoyan Li; Shengjie Sun; Lijie Wang; Shunchang Jiao
Journal:  Tumour Biol       Date:  2012-09-05

10.  Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.

Authors:  Alberto Martin; Fernando Salvador; Gema Moreno-Bueno; Alfredo Floristán; Cristina Ruiz-Herguido; Eva P Cuevas; Saleta Morales; Vanesa Santos; Katalin Csiszar; Pierre Dubus; Jody J Haigh; Anna Bigas; Francisco Portillo; Amparo Cano
Journal:  EMBO J       Date:  2015-03-10       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.